Pancreatic cancer is among the most aggressive cancer types, with survival rates being very low and current treatment being quite ineffective. To address this unmet medical need, HCW Biologics Inc. has developed and presented preclinical data for their T-cell engager approach – HCW11-018.
Nectin-4 is a cell-adhesion molecule that is highly expressed in several malignancies, including bladder, colorectal, lung and breast cancers, while exhibiting minimal expression in most normal adult tissues.
Researchers from Compass Therapeutics Inc. detailed the preclinical characterization of CTX-10726, a bispecific, tetravalent antibody that simultaneously targets VEGF-A and PD-1.
Human endogenous retroviruses (HERVs) are residues from ancient viral infections that have become integrated into the human genome. One of them – HERV-K – is aberrantly reactivated in solid tumors but silent in healthy tissues.
The limited efficacy of cancer immunotherapy is usually attributed to suboptimal antitumor T-cell generation, as well as impaired immunological memory development. MDX-2004 is a trispecific antibody-fusion protein developed by Modex Therapeutics Inc. that targets CD3, CD28 and CD137 on human T cells, which was designed to overcome these limitations by rejuvenating the immune system and enhancing antitumor immunity.
Researchers from Chantibody Therapeutics Inc. presented the preclinical characterization of CT-111, a trispecific antibody engineered to simultaneously target PD-1, CTLA-4, and VEGF.
Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
The inhibition of PD-L1 and VEGF individually or in combination has shown efficacy across several solid tumor types, but not all patients respond to therapy or respond for short duration. IMM-2510 is a novel bispecific antibody developed by Immuneonco Biopharmaceuticals Inc. that targets both PD-L1 and VEGF, thus achieving both angiogenesis inhibition and immune checkpoint blockade.
Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-260, an inhibitor of the co-repressor of repressor element-1 silencing transcription (CoREST) deacetylase complex, designed to treat immunotherapy-resistant STK11-mutant tumors.
